FDAnews
www.fdanews.com/articles/85028-callisto-to-study-atiprimod-in-carcinoid-tumors

CALLISTO TO STUDY ATIPRIMOD IN CARCINOID TUMORS

March 3, 2006

Callisto Pharmaceuticals plans to launch an additional indication for clinical development of its drug candidate Atiprimod based on encouraging clinical results that showed a clear response in carcinoid patients taking the drug.

Based on the clinical data, the company plans to initiate a Phase I/II trial of Atiprimod in carcinoid cancer patients with advanced tumors that it plans to open at several sites in the next few months.

Carcinoid tumors, or carcinoids, originate in hormone-producing cells of the gastrointestinal (GI) tract, the respiratory tract, the hepatobiliary (liver) system and the reproductive glands. The most common site of origin is the GI tract, with tumors often developing in the rectum, and other sections of the small intestine. There are currently no FDA-approved drugs for these types of tumors.